Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise despite higher R&D expenses and a decline in operating margin.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise despite higher R&D expenses and a decline in operating margin.
